Protocol Ledger

NCT07116967 · Phase III · RECRUITING

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Interventional Phase III clinical trial protocol NCT07116967 sponsored by Bristol Myers Squibb in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-22 Enrollment: 3,040 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07116967
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,040 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07116967
Protocol FieldVerified Registry Value
NCT IdentifierNCT07116967
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,040 participants (ESTIMATED)
Registered Start Date2025-09-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07116967
Hospital Research SiteLocationSite Profile
California Dermatology & Clinical Research InstituteEncinitas, CAOpen Hospital Dossier ->
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI